RJFSA
TGTX icon

Raymond James Financial Services Advisors’s TG Therapeutics TGTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,500
Closed -$9K – 2577
2017
Q1 		$9K Buy
+15,500
New +$111K ﹤0.01% 2416

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's TGTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its TG Therapeutics (TGTX) stake by 0.28% in Q3 2024, selling an estimated $6.64K and leaving 108,969 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Raymond James Financial Services Advisors first reported a position in TGTX in Q4 2016 and has held it in 32 quarters since. The position peaked at $6.42M in Q4 2020. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 108,969 shares of TG Therapeutics worth $2.55M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 304 TG Therapeutics shares in Q3 2024, an estimated $6.64K.
  • TG Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1605 holding.
  • Raymond James Financial Services Advisors first reported a position in TG Therapeutics in Q4 2016 and has held it in 32 quarters since.
  • Raymond James Financial Services Advisors's TG Therapeutics position peaked at $6.42M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.